We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Allergy Therapeutics has initiated a biomarker study at Imperial College London, which will aim to evaluate its novel virus like particle (VLP) based peanut allergy vaccine candidate.